Management system improvement of the research centres by FMEA implementation
Тhe relevance of using FMEA in a research centre management is that it helps to actively manage risks and prevent them, which positively affects the whole functioning of the organization. Its regular use allows to improve the interaction between the departments and members of the organization and also deepens the understanding of the processes by staff.
The purpose of the study is to design science and practical approaches for FMEA implementation in the management system of the research centres as a basic tool for risk management.
Materials and methods: analysis, synthesis, empirical methods, logical method, generalization method of modeling.
Results. An important step of this work was to determine advantages, disadvantages, conditions for successful implementation of FMEA method and possible errors in applying the method.
Conclusions. During the study, a comprehensive analysis of FMEA applying features as a key tool for risk management in a research center (medical, laboratory, bioanalytics) was conducted.
The scientific importance of the work consists that on the basis of conducted studies, developed proposals for the improvement of the innovation project to implement FMEA for the centres.
The value of the research. The algorithm of realization of the project, which should increase the interest centres in the analysis, and also proposed other initiatives related to FMEA. It could be relevant for a wide range of centres (design sequence charts of the processes as a way of standardization and training in a cause-and-effect analysis).
Q9 Quality Risk Management. FDA Guidance for Industry, ICH June (2006), / U.S. Department of Health and Human Services / Food and Drug Administration / Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) – [Online], available at: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm073511.pdf. (Accessed 15 November 2018) ), (In Ukrainian).
Zupanets K. O., Dobrova V. E. (2015), “Conceptual provisions on risk management in the clinical trial of the medicinal product at the site of the study”, Upravlìnnâ, ekonomìka ta zabezpečennâ âkostì v farmacìï, vol. 6 (44) pp. 49 – 57.
State Committee (2013)“DSTU ISO/IEC 31010:2013: Risk management – Risk assessment techniques. [Online], available at: http://online.budstandart.com/ua/catalog/doc-page.html?id_doc=66723 (Accessed 17 November 2018), (In Ukrainian).
Rosenthal R. (2010), “FMEA Methodology. A way to improve product quality”, JeLEKTRONIKA: Nauka, Tehnologija, Biznes, [Online], available at: http://www.electronics.ru/journal/article/131 (Accessed 12 November 2018).
Zupanets K.O., Ratushna K. L., Dobrova V.E. (2015), “Risk Assessment of data quality using the FMEA analysis method”, Klinichna farmatsiia, vol. 3, Tom19, pp. 4–10.
Sutrisno A., Lee T-R. (2011), “Service reliability assessment using failure mode and effect analysis (FMEA): survey and opportunity roadmap”, International Journal of Engineering, Science and Technology, vol. 3 No. 7, pp. 25-38.
McDermott R., Mikulak R., Beauregard M. (2009), The Basics of FMEA, New York, USA, Productivity Press of Taylor & Francis Group, 91p.
Potential Failure Mode and Effects Analysis (FMEA) (2008), Reference Manual. Chrysler LLC, Ford Motor Company, General Motors Corporation. - Fourth edition, June. 142 p.
Zupanets K.O., Dobrova V.E., Proskurnia O.M. (2015), “Science justification of combined management system of clinical trial on clinical site”, Upravlìnnâ, ekonomìka ta zabezpečennâ âkostì v farmacìï, vol. 4 (42) pp. 60 – 66.
Zupanets K.O., Dobrova V.E. (2016), “Analysis of expert opinions on the implementation of conceptual provisions for risk management in clinical trials of medicinal products”, Zaporozhskyj medytsynskyj zhurnal, vol. 3 (96) pp. 93 – 98.
Lebedinska O. M., Proskurnia O.M. (2015), “Actuality of the FMEA method in clinical research centers”, Zbirnyk materialiv IKh naukovo-praktychnoi konferentsii s mizhnarodnoiu uchastiu [Collection of materials of the IX scientific and practical conference with international participation] Upravlinnia iakistiu v farmatsii [Quality management in pharmacy], Kharkov, Ukraine, 22 May, pp 76.
Schaeffers M., Murphy S. (2015), How to Create a Successful FMEA Program. SixSigma, [Online], available at: http://www.isixsigma.com/tools-templates/fmea/how-to-create-a-successful-fmea-program (Accessed 15 November 2018).
Human Factors in Patient Safety. Review of Topics and Tools. (2009), Report for Methods and Measures Working Group of WHO Patient Safety, World Health Organization, April, [Online], available at: http://www.who.int/patientsafety/research/methods_measures/human_factors/human_
factors_review.pdf (Accessed 15 November 2018).
Mendes M.E., Ebner P.R., Romano P., Neto M.P., Sant’anna A., Sumita N.M. (2013), Practical aspects of the use of FMEA tool in clinical laboratory risk management / J Bras Patol Med Lab, June, vol.49, n.3, ph.174-181.
Rath.F. (2008), Tools for development a quality management program: proactive tools (process mapping, value stream mapping, fault tree analysis, and Failure Mode and Effects Analysis, Int. J. Radiation Oncology Biol. Phys., Vol.71, No.1, Supplement, pp. 187-190.
Ashley L., Armitage G., Neary M., Hollingsworth G. A (2010), Practical Guide to Failure Mode and Effects Analysis in Health Care: Making the Most of the Team and Its Meetings / The Joint Commission Journal on Quality and Patient safety, Vol. 36 No. 8, August, pp. 351-358.